Search clinical trials for: B cell line

Total 489506 results

Janssen Research & Development, LLC

Not yet recruiting

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-10)

Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb

Not yet recruiting

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France (URADJ)

Urothelial Carcinoma

France
Bristol-Myers Squibb

Recruiting

Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy

Peripheral T-cell Lymphoma

Japan
Jinghui Wang

Recruiting

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

Lung Cancer

China
N.N. Petrov National Medical Research Center of...

Recruiting

High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors (GERMAN)

Germ Cell Tumor

Russian Federation
University of Cologne
AstraZeneca

Not yet recruiting

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE)

Small Cell Lung Carcinoma
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

First-line Advanced NSCLC Patients

China
Celgene

Not yet recruiting

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Changzhou No.2 People's Hospital

Not yet recruiting

FMT+Immunotherapy+Chemotherapy as First-line Treatment for Driver-gene Negative Advanced NSCLC

Non-small Cell Lung Cancer
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Changhai Hospital
Shanghai Chest Hospital; Shanghai Changzheng Hospital; First Affiliated Hospital... and other collaborators

Recruiting

High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Non-Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI

Non-small Cell Lung Cancer

China
AstraZeneca

Not yet recruiting

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC (FOREFRONT)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Neoplasms by Site | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms

China
University Hospital, Essen
German Cancer Aid

Not yet recruiting

Exercise in Patients With Advanced Non-small Cell Lung Cancer (BREATH)

Advanced Lung Carcinoma | NSCLC Stage IV | NSCLC Stage IIIB | First Line Treatment | Second Line Treatment | Palliative Treatment | NSCLC Stage IIIC

Germany
The Central Hospital of Lishui City

Not yet recruiting

Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC

Carcinoma | Small Cell Lung Cancer

China
Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of...

Not yet recruiting

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma
Tufts Medical Center
National Cancer Institute (NCI)

Not yet recruiting

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

NSCLC

China
Daiichi Sankyo
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Extensive Stage-small Cell Lung Cancer
Bristol-Myers Squibb

Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy

Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Lymphocytic Leukaemia

Belgium
Sun Jing

Not yet recruiting

Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status

Colorectal Neoplasms | Colorectal Cancer
Neonc Technologies, Inc.

Not yet recruiting

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

High Grade Glioma | Pineocytoma | Diffuse Midline Glioma, H3 K27M-Mutant | Spinal Cord Tumor | Pediatric Tumor of CNS | Pediatric Tumor of Brain | Pediatric Tumor of Brain Stem | Choroid Plexus Carcinoma, Childhood
The First Affiliated Hospital, Guangzhou University...

Not yet recruiting

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Advanced NSCLC
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Spain, Italy, Japan, Brazil, Taiwan, Korea, Republic of, Australia, Austria, Canada, Poland, United States, Belgium, United Kingdom, Turkey, Hungary, Germany, India
Celgene

Not yet recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

United States, Canada, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Japan, Korea, Republic of, Malaysia, Mexico, New Zealand, Norway, Poland, Portug... and more
Imperial College London

Not yet recruiting

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial (MAST)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Lymphoblastic Leukaemia

United Kingdom
AstraZeneca
Daiichi Sankyo

Not yet recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

China, Taiwan, Korea, Republic of, Australia
UNC Lineberger Comprehensive Cancer Center
Bellicum Pharmaceuticals

Not yet recruiting

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Breast Cancer | Triple Negative Breast Cancer | Relapse | Resistant Cancer

United States
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Multiple Myeloma | Newly Diagnosed Multiple Myeloma | Autologous Stem Cell Transplantation

United States
Bristol-Myers Squibb

Recruiting

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Advanced Renal Cell Carcinoma (aRCC)

United States
Guangzhou Institute of Respiratory Disease

Recruiting

To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

China
Nationwide Children's Hospital
Pfizer

Not yet recruiting

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | WHO Grade III Glioma | WHO Grade IV Glioma | Infant Type Hemispheric Glioma | Diffuse Midline Glioma, H3K27-altered

United States, Australia, Canada, Germany, Netherlands
Guangzhou Institute of Respiratory Disease

Recruiting

A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Hunan Cancer Hospital

Not yet recruiting

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Melanoma
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage
Peking University First Hospital

Recruiting

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Renal Cell Carcinoma, Clear Cell, Somatic

China
Fudan University

Not yet recruiting

Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NSCLC Stage IV

China
Fundación Oftalmológica de Santander Clínica Carlos...
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS

Not yet recruiting

Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment (GvHD)

Graft Versus Host Disease
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Ovarian Cancer | Epithelial Ovarian Cancer | Ovary Neoplasm | Recurrent

United States
OX2 Therapeutics

Recruiting

CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults

Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent High Grade Glioma

United States
Merck Sharp & Dohme LLC

Not yet recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Non-small Cell Lung Cancer (NSCLC)
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

Study of BMS-986393 a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Multiple Myeloma

United States, Canada
UNC Lineberger Comprehensive Cancer Center

Not yet recruiting

DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics (DISCOVERY)

Lymphoma | Leukemia | Multiple Myeloma | Hematologic Malignancies | Blood Cancers

United States
Inhibrx, Inc.

Recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Gestional Trophoblastic Neoplasia Ultrasound Assessment: Titanium Study (TITANIUM)

Describe Typical Gray Scale/Color Doppler Ultrasound Features of Gestational Trophoblastic Neoplasia at the US Examination | To Assess if There Are Differences at the Baseline US Scan Between Low-risk and High-risk Patients | To Identify Ultrasound Predictors of Resistance to First-line... and other conditions

Italy
Tianjin Medical University Cancer Institute and...
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Irinotecan Liposome Injection Combined With 5-FU/LV± Immunotherapy in First-line Gemsitabine + Immunoprogressive Patients With Metastatic Biliary Tract Cancer

Metastatic Biliary Tract Cancer

China
Tongji University
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Camrelizumab

Search clinical trials for: B cell line

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations